<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259714</url>
  </required_header>
  <id_info>
    <org_study_id>0509000646</org_study_id>
    <secondary_id>1034978.1.R06791..721688.02</secondary_id>
    <nct_id>NCT00259714</nct_id>
  </id_info>
  <brief_title>Dialysate Sodium Individualization in Hemodialysis</brief_title>
  <official_title>Hemodynamic and Hormonal Responses to Dialysate Sodium Individualization in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Satellite Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Salt and water excess is an essential mechanism of hypertension. This is particularly
      relevant to patients with end stage kidney disease (ESKD) on dialysis. We have demonstrated
      that individualization of the sodium concentration in the dialysate as to match the patient's
      own serum sodium concentration leads to less thirst, interdialytic weight gain, and better BP
      control in hypertensive patients. In this study we will evaluate the mechanisms underlying
      this response by measuring systemic hemodynamics, body volume spaces, and biochemical marker
      of volume status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent evidence from our group shows that individualization of the sodium concentration in
      the dialysate to match the patient's own serum sodium results in less thirst, less
      interdialytic weight gain, less HD-related symptoms, and better blood pressure control in
      hypertensive subjects. In this project we will evaluate the effect of dialysate sodium
      individualization on systemic hemodynamics, body volume compartments and biochemical markers
      of volume control in hypertensive hemodialysis patients. We will use a single-blind
      cross-over design with randomized blocks. After a 3-week baseline period where pre-HD serum
      sodium will be measured weekly to establish each patient's average serum sodium, subjects
      will be randomized to 3 weeks on standard dialysate sodium (140 mmol/L) or individualized
      dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline
      period), then crossed over to the other for another 3 weeks after a 1-week washout period
      (dialysate Na 140 mmol/L). The remainder of the dialysis prescription, prescribed dry weight
      and vasoactive drugs will remain unchanged throughout the study. Clinical information,
      pre/intra/post-HD blood pressure and thirst scores will be measured weekly at the mid-week
      dialysis session. In addition, we will measure systemic hemodynamics (cardiac output and
      systemic vascular resistance), bioimpedance measurements of intracellular and extracellular
      volume, arterial stiffness (aortic augmentation index, aortic pulse wave velocity),
      interdialytic (44h) ambulatory BP monitoring, and plasma BNP, renin, aldosterone and
      norepinephrine at baseline and at the end of each block.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Protocol was not feasible - only 1 of 18 enrollees completed procedures.
  </why_stopped>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BP changes on 44-h ABPM</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in cardiac output and systemic vascular resistance</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in intracellular and extracellular volume</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in measured biochemical markers</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in augmentation index</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circadian BP profile on 44-h ABPM</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Hypertension</condition>
  <condition>Hemodialysis Patients</condition>
  <arm_group>
    <arm_group_label>standard dialysate sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the control phase of the study, the prescribed dialysate sodium is 140 mEq/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dialysate sodium individualization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>.Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (&quot;individualized&quot;).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dialysate sodium individualization</intervention_name>
    <description>Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (&quot;individualized&quot;).</description>
    <arm_group_label>dialysate sodium individualization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard dialysate sodium</intervention_name>
    <description>The prescribed dialysate sodium is 140 mEq/L</description>
    <arm_group_label>standard dialysate sodium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ESKD on hemodialysis

          -  Hypertension, defined as average pre-HD BP &gt;150/85 mmHg or use of antihypertensive
             drugs

          -  Average pre-HD serum sodium &lt;139 mmol/L

        Exclusion Criteria:

          -  Intradialytic hypotension

          -  Atrial fibrillation or other chronic tachyarrhythmia (due to effects on measuring
             equipment)

          -  Uncontrolled hypertension (average pre-HD BP &gt;200/105 mmHg)

          -  Uncontrolled diabetes mellitus (due to problems on interpretation of serum sodium
             values)

          -  Debilitating illness

          -  Inability to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldo J Peixoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University and VA Connecticut Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Davita New Haven Dialysis Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>de Paula FM, Peixoto AJ, Pinto LV, Dorigo D, Patricio PJ, Santos SF. Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients. Kidney Int. 2004 Sep;66(3):1232-8. Erratum in: Kidney Int. 2004 Nov;66(5):2108.</citation>
    <PMID>15327422</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2005</study_first_submitted>
  <study_first_submitted_qc>November 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <last_update_submitted>July 21, 2016</last_update_submitted>
  <last_update_submitted_qc>July 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>sodium</keyword>
  <keyword>dialysate</keyword>
  <keyword>hemodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

